Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Inactivated |
Clinical data | |
Routes of administration | Intramuscular |
Identifiers | |
DrugBank |
QazCovid-in, commercially known as QazVac, [1] [2] is a COVID-19 vaccine developed by the Research Institute for Biological Safety Problems in Kazakhstan. [3] [4] QazCoVac-P is a second COVID-19 vaccine developed by the Kazakh Biosafety Research Institute and in clinical trials. [5]
The vaccine can be stored at standard refrigeration temperatures (2 °C-8 °C) and is a two-dose régime with the doses administered twenty-one days apart. [6] The vaccine was first manufactured by Kazakhstan's Research Institute of Biological Safety Problems. Production capacity has been capped at 50,000 doses per month.[ citation needed]
Beginning in June 2021, the vaccine is slated [7] to be packaged in large bulk to be bottled in Turkey by a major Turkish company. [8] This will allow for a production capacity of 500,000-600,000 doses per month. [9] The contract is still being negotiated, [10] despite earlier claims suggesting that the deal had already been finalized. [11] [12]
In October 2021, it was announced that the vaccine would be supplied to Afghanistan and other countries in 2022. [13]
In September 2020, QazVac started in Phase I/II clinical trials. [14]
In December 2020, QazVac is currently in Phase III clinical trials, which is expected to be fully completed by 9 July 2021. [2] [8] It is unclear when the first preliminary results will be published. [15] [12]
The administration of the vaccine for the general population began at the end of April 2021. [16] The Research Institute Kunsulu Zakarya's Director General's justification is that the trial is almost 50% completed and "people who have received [the] vaccine feel well; there have been no side-effects and the effectiveness of the vaccine is high". [8]
In September 2021, a study was published to eClinicalMedicine, published by The Lancet. The study’s findings were that the “QazCovid-in® vaccine was safe and well-tolerated and induced predominantly mild adverse events; no serious or severe adverse events were recorded in both trials.” [17]
The first batch of 50,000 doses was delivered on 26 April 2021, and vaccination began shortly after.[ citation needed] In June 2021, the capacity will increase to 100,000 doses per month, regardless of the contract for bottling in Turkey. [18]
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Inactivated |
Clinical data | |
Routes of administration | Intramuscular |
Identifiers | |
DrugBank |
Part of a series on the |
COVID-19 pandemic |
---|
|
Medical response |
|
COVID-19 portal |
QazCovid-in, commercially known as QazVac, [1] [2] is a COVID-19 vaccine developed by the Research Institute for Biological Safety Problems in Kazakhstan. [3] [4] QazCoVac-P is a second COVID-19 vaccine developed by the Kazakh Biosafety Research Institute and in clinical trials. [5]
The vaccine can be stored at standard refrigeration temperatures (2 °C-8 °C) and is a two-dose régime with the doses administered twenty-one days apart. [6] The vaccine was first manufactured by Kazakhstan's Research Institute of Biological Safety Problems. Production capacity has been capped at 50,000 doses per month.[ citation needed]
Beginning in June 2021, the vaccine is slated [7] to be packaged in large bulk to be bottled in Turkey by a major Turkish company. [8] This will allow for a production capacity of 500,000-600,000 doses per month. [9] The contract is still being negotiated, [10] despite earlier claims suggesting that the deal had already been finalized. [11] [12]
In October 2021, it was announced that the vaccine would be supplied to Afghanistan and other countries in 2022. [13]
In September 2020, QazVac started in Phase I/II clinical trials. [14]
In December 2020, QazVac is currently in Phase III clinical trials, which is expected to be fully completed by 9 July 2021. [2] [8] It is unclear when the first preliminary results will be published. [15] [12]
The administration of the vaccine for the general population began at the end of April 2021. [16] The Research Institute Kunsulu Zakarya's Director General's justification is that the trial is almost 50% completed and "people who have received [the] vaccine feel well; there have been no side-effects and the effectiveness of the vaccine is high". [8]
In September 2021, a study was published to eClinicalMedicine, published by The Lancet. The study’s findings were that the “QazCovid-in® vaccine was safe and well-tolerated and induced predominantly mild adverse events; no serious or severe adverse events were recorded in both trials.” [17]
The first batch of 50,000 doses was delivered on 26 April 2021, and vaccination began shortly after.[ citation needed] In June 2021, the capacity will increase to 100,000 doses per month, regardless of the contract for bottling in Turkey. [18]
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|